Forte Biosciences Inc
FBRX11.435USD
+1.135+11.02%
收盘 11/06, 16:00（美东）报价延迟15分钟
140.44M总市值
亏损市盈率 TTM
关于 Forte Biosciences Inc 公司
Forte Biosciences, Inc. 是一家专注于自身免疫和自身免疫相关疾病的临床阶段生物制药公司。该公司正在推进其候选产品 FB-102，这是一种专有分子，具有广泛的自身免疫应用潜力，包括移植物抗宿主病 (GvHD)、白癜风和斑秃 (AA) 等适应症。该公司的 FB-102 项目专注于利用 CD122 拮抗剂解决与这些适应症有关的关键途径。CD122 是 IL-2/IL-15 受体的亚基，IL-2/IL-15 受体是 NK 细胞和 T 细胞亚群的关键调节剂。该公司拥有一项美国专利，用于施用革兰氏阳性菌和革兰氏阴性菌以及代谢物的组合，以治疗多种皮肤病。该公司的子公司包括 Forte Subsidiary, Inc.、Forte Biosciences Emerald Limited 和 Forte Biosciences Australia Pty Ltd。
Forte Biosciences Inc简介
公司代码FBRX
公司名称Forte Biosciences Inc
上市日期Apr 13, 2017
CEODr. Paul A. Wagner, Ph.D.
员工数量14
证券类型Ordinary Share
年结日Apr 13
公司地址3060 Pegasus Park Drive
城市DALLAS
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编75247
电话13106186994
网址https://www.fortebiorx.com/home/default.aspx
公司代码FBRX
上市日期Apr 13, 2017
CEODr. Paul A. Wagner, Ph.D.
Forte Biosciences Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
82.09K
+1.42%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.70K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
82.09K
+1.42%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.70K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 11月4日 周二
更新时间: 11月4日 周二
持股股东
股东类型
持股股东
持股股东
占比
Federated Hermes Global Investment Management Corp.
13.15%
Fred Alger Management, LLC
13.02%
Janus Henderson Investors
11.22%
OrbiMed Advisors, LLC
9.63%
Tybourne Capital Management (HK) Limited
6.33%
其他
46.65%
持股股东
持股股东
占比
Federated Hermes Global Investment Management Corp.
13.15%
Fred Alger Management, LLC
13.02%
Janus Henderson Investors
11.22%
OrbiMed Advisors, LLC
9.63%
Tybourne Capital Management (HK) Limited
6.33%
其他
46.65%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
45.54%
Hedge Fund
25.35%
Private Equity
10.18%
Investment Advisor
7.24%
Corporation
3.95%
Individual Investor
1.03%
Research Firm
0.08%
其他
6.64%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
77
10.98M
88.35%
+3.99M
2025Q2
80
7.19M
109.15%
+1.76M
2025Q1
80
5.91M
89.79%
+471.51K
2024Q4
82
5.78M
90.44%
+3.18M
2024Q3
72
948.15K
58.94%
-63.60K
2024Q2
79
972.89K
60.86%
-40.06K
2024Q1
108
982.74K
67.53%
-37.22K
2023Q4
121
973.92K
67.03%
-54.29K
2023Q3
139
1.01M
71.78%
+97.73K
2023Q2
175
455.32K
54.14%
-352.22K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Federated Hermes Global Investment Management Corp.
1.48M
11.89%
+406.41K
+37.90%
Aug 31, 2025
Fred Alger Management, LLC
1.62M
13.02%
+708.04K
+77.75%
Jun 30, 2025
Janus Henderson Investors
1.39M
11.22%
+474.85K
+51.61%
Jun 30, 2025
OrbiMed Advisors, LLC
1.20M
9.63%
+603.87K
+101.82%
Jun 30, 2025
Tybourne Capital Management (HK) Limited
786.65K
6.33%
+166.67K
+26.88%
Jun 30, 2025
BVF Partners L.P.
588.34K
4.73%
-5.94K
-1.00%
Jun 30, 2025
Cable Car Capital LLC
500.00K
4.02%
+280.40K
+127.68%
Jun 30, 2025
Sphera Funds Management Ltd.
495.11K
3.98%
+495.11K
--
Jun 30, 2025
The Vanguard Group, Inc.
486.92K
3.92%
+397.97K
+447.40%
Jun 30, 2025
Ikarian Capital LLC
476.44K
3.83%
-132.78K
-21.80%
Jun 30, 2025
查看更多
持股ETF
更新时间: 20 小时前
更新时间: 20 小时前
机构名称
占比
Alger 35 ETF
3.45%
Texas Capital Texas Small Cap Equity Index ETF
0.07%
iShares Micro-Cap ETF
0.02%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Alger Mid Cap 40 ETF
0%
Avantis US Small Cap Equity ETF
0%
Alger 35 ETF
占比3.45%
Texas Capital Texas Small Cap Equity Index ETF
占比0.07%
iShares Micro-Cap ETF
占比0.02%
Dimensional US Core Equity 1 ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
Fidelity Nasdaq Composite Index ETF
占比0%
Alger Mid Cap 40 ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
公告日期
类型
比率
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
